Redeye retains its positive view on Speqta following the Strategic Review.
Redeye endorses aXichem receiving yet another aXivite order from its Polish distributor BART.
Kostnaderna tickade upp Rapporten för Q4 2021 summerade ett händelserikt kvartal, där den kliniska p...
Redeye retains its positive view on Transtema following the acquisition of Tessta Connect.
Redeye leaves a comment on InDex Pharmaceuticals following its Capital Markets Day, where the compan...
Modus Therapeutics Holding AB (Modus or the Company) has developed a compound that can revolutionise...
Sedan börsnoteringen fortsätter Candles att växa med ett starkt orderflöde och med miljövänliga doft...
Redeye is pleased with the news that Safello and Avanza are exploring a potential partnership.
Redeye was surprised by the strong earnings and that sales managed to hold up reasonably against str...
The essential Q3 (November-January) feedback is that the FDA process progresses without significant ...
Med distributörer och utvalda sjukhus i Europa ska 2cureX bygga en marknad för bättre cancerbehandli...
Redeye updates estimates on Aspire Global which is a now pure B2B company following the divestment o...
Redeye states that Q4 came in below estimates and that the rapid acceleration is likely pushed forwa...
Swedish Stirling förbereder sig inför kommersiell utrullning och har fått ett viktigt besked kring p...
NAGATO växte 300% 2021 Tourns omsättning i Q4'21 blev 41 mkr och växte därmed 34% y/y.
Redeye endorses 2cureX launching its third test, IndiTreat Explore, and thereby completing its portf...
Redeye retains its positive view on Speqta, currently trading below net cash.
Redeye retains its Base Case and long-term forecasts following a mixed Q4 report with strong sales a...
Fantasma Games AB (”Fantasma” eller ”Bolaget”) utvecklar och producerar spel till den globala casino...
Redeye is still optimistic on the case as the Q3 report is showing strong growth across the board.
